Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
"Differing opinions and debates are welcome"
Thats not true I'm afraid. TG is a paranoid echo chamber uninterested in discovering new aspects and if the powers that be (incorrectly) label you as asking for views and opinions on other aspects of interest, then Albert boots you out.
"@WAG - I think it is important to separate two types of discussions. 1) would be for ava6k, either for other indications (breast, ovarian) or for certain geographies and the 2) would be to get Precision to attach a bespoke warhead."
I agree Jive - but also think there's a 3rd type of discussion involving something not core to Avacta such as a radioligand or an old style chemo which would be a smaller interim licence to tide us over until more data and discussions to get the first major collaboration on good terms, rather than as someone pressed for cash.
Thanks for the clues JT
I did a few cross referenced googles and found this
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848530/
Haven't read it all yet but seems to be relevant
Thanks JT
That sounds a plausible working assumption and probably where my thinking had taken me.
Mr O i think alluded to a situation where at low concentrations dox gets cleared from the heart implying no cardiotox if levels are kept low enough
Leaves the 7 extra cycles as bit of a mystery still - i wouldn't be suprised in the end to be told that they go on past 7. If they do it would be great to have it explained why
7 more cycles mentioned here was unexplained
Might have been saying that somecardiotox seen at C3 dose for this particular patient.
But then elsewhere the message is no cardiotox seen
IMO clarification in this area would have been useful but overall probably of no real signifigance
MTD for me is bit of a red herring
What I'd like is a clear explanation of how the cumulative cardiotoxicity acrues with various dosing regimes.
As it seems to me that this is the overall limiting factor
FM in Q&A mentioned that C-max is a strong driver
@JT
PS I have my own views on what we may hear shortly from the FDA on STS.
If that news arrives too, should be positive.
The lasting financial benefit will arise when a third party starts validating our IP with commercial deals involving the suitably sized upfront cash that we need.
@JT I'm a fan of AVCT and have been invested for years, waiting patiently for commercialisation.
I know, as you say, that their IP has far far more potential than most other biotechs not least because they own two platforms that might end up being widely applied in a number of different potential commercial models.
What annoys me - as I think it's ultimately counterproductive, especially from those who know better, is selective analysis/comparison such as "all nasdaq phase1/2 biotech are valued 6 times higher than AVCT."
I am well aware of the AVCT release in January - all those who follow "knows" "it works". But as far as the wider market is concerned P1 is yet to be completed and full Big Pharma friendly data is still to be released ( imminently ).
One such selective fact not mentioned is that at the relevant time prior to results NUVL had something like $ 400m cash on hand multi year runway. While AVCT don't.
I agree the rise after NUVL results was 50-80% not the 6x alluded to by others.
I agree as companies progress their candidates through advancing phases of trials, in the absence of scientific setbacks, one would expect the market value to also advance yet. AVCT aren't there yet.
I wasn't going to post this as I don't particularily enjoy abuse and don't think AVCT will do this, as I believe they are working on other non dilutive methods.
However it has gone unreported that the first thing NUVL did after their trial results release was a $300m raise to top their cash runway up to 3 years. It's the way the US markets work as they have the depths of liquidity we don't have in the UK.
Good luck to us all on Wednesday.
@JT " If we compare Avacta to they US-listed equivalents, we are drastically under-priced."
While UK market luquidity is crap, a proper comparison of Nuvalent $NUVL for example and their MV prior to releasing their phase I data, in 2022 I think it was, there wasn't actually that great a disparity in valuations allowing for different times/ market conditions and cash runways.
Certainly much closer comparison than some like to think, or say.
Under the terms of the agreement, Avidity will receive $100 million upfront, which includes a $60 million cash payment as well as the purchase of approximately $40 million of Avidity common stock at a purchase price of $7.88 per share. Avidity is also eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from this collaboration.
Most are hopeing AVCT will manage a better deal!